Rangappa Kanchugarakoppal Subbegowda

Title: **Rangappa Kanchugarakoppal Subbegowda: A Pioneer in Cancer Research**

Introduction

Rangappa Kanchugarakoppal Subbegowda, based in Mysore, India, is a distinguished inventor renowned for his significant contributions to cancer treatment research. With a total of 2 patents to his name, Subbegowda has focused his efforts on developing innovative compounds aimed at combating various types of cancer.

Latest Patents

His latest inventions include:

1. **Small molecule inhibitors of BCL-2-associated death promoter (BAD) phosphorylation** - This patent concerns compounds that inhibit the phosphorylation of the BCL-2-associated death promoter (BAD). These compounds exhibit anti-apoptotic activity and have promising applications in treating several cancers, including breast, endometrial, ovarian, liver, colon, prostate, and pancreatic cancer.

2. **Compounds useful in inhibiting human trefoil factor 3** - Also featured in his patent portfolio are compounds designed to inhibit the human trefoil factor 3, which have implications in various therapeutic applications.

Career Highlights

Throughout his career, Subbegowda has held positions at esteemed institutions, notably the National University of Singapore and the University of Mysore. His work has emphasized the importance of innovative research in addressing critical medical challenges.

Collaborations

Rangappa's research journey has included collaboration with notable colleagues such as Peter Edward Lobie and Vijay Kumar Pandey. These partnerships have enriched his work and fostered advancements in the field of cancer research.

Conclusion

Rangappa Kanchugarakoppal Subbegowda’s contributions to the development of cancer treatment compounds mark him as a significant figure in the world of medical research. His ongoing quest for innovative solutions showcases the vital role of inventors in enhancing healthcare and improving patient outcomes.